Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
    2.
    发明授权
    Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors 有权
    咪唑并[1,2-A]吡啶衍生物及其作为mGluR2受体的正变构调节剂的用途

    公开(公告)号:US08785486B2

    公开(公告)日:2014-07-22

    申请号:US12742638

    申请日:2008-11-12

    CPC分类号: C07D471/04 C07D519/00

    摘要: The present invention relates to novel compounds, in particular novel imidazo[1,2-a]piridine derivatives according to Formula (I). The compounds according to the invention are positive allosteric modulators of metabotropic receptors-sub-type 2 (‘mGluR2’) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.

    摘要翻译: 本发明涉及新型化合物,特别是根据式(I)的新型咪唑并[1,2-a]吡啶衍生物。 根据本发明的化合物是代谢型受体 - 亚型2('mGluR2')的正性变构调节剂,其可用于治疗或预防与谷氨酸功能障碍相关的神经和精神障碍以及代谢代谢受体的mGluR2亚型的疾病 参与。 特别地,这些疾病是选自焦虑,精神分裂症,偏头痛,抑郁症和癫痫组的中枢神经系统疾病。 本发明还涉及制备这些化合物和组合物的药物组合物和方法,以及这些化合物用于预防和治疗其中涉及mGluR2的疾病的用途。

    IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
    4.
    发明申请
    IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS 有权
    咪唑并[1,2-A]吡啶衍生物及其作为MGLUR2受体的阳性免疫调节剂的用途

    公开(公告)号:US20110009441A1

    公开(公告)日:2011-01-13

    申请号:US12742638

    申请日:2008-11-12

    CPC分类号: C07D471/04 C07D519/00

    摘要: The present invention relates to novel compounds, in particular novel imidazo[1,2-a]piridine derivatives according to Formula (I). The compounds according to the invention are positive allosteric modulators of metabotropic receptors-sub-type 2 (‘mGluR2’) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.

    摘要翻译: 本发明涉及新型化合物,特别是根据式(I)的新型咪唑并[1,2-a]吡啶衍生物。 根据本发明的化合物是代谢型受体 - 亚型2('mGluR2')的正性变构调节剂,其可用于治疗或预防与谷氨酸功能障碍相关的神经和精神障碍以及代谢代谢受体的mGluR2亚型的疾病 参与。 特别地,这些疾病是选自焦虑,精神分裂症,偏头痛,抑郁症和癫痫组的中枢神经系统疾病。 本发明还涉及制备这些化合物和组合物的药物组合物和方法,以及这些化合物用于预防和治疗其中涉及mGluR2的疾病的用途。

    3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
    5.
    发明授权
    3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives 有权
    3-氰基-4-(4-四氢吡喃 - 苯基) - 吡啶-2-酮衍生物

    公开(公告)号:US08906939B2

    公开(公告)日:2014-12-09

    申请号:US12529568

    申请日:2008-03-07

    IPC分类号: C07D405/12 A61K31/4433

    CPC分类号: C07D405/12

    摘要: The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) including any stereochemically isomeric form thereof, or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein all radicals are defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic glutamate receptors subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and such compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.

    摘要翻译: 本发明涉及新化合物,特别是包括其任何立体化学异构形式的式(I)的新型吡啶酮衍生物或其药学上可接受的盐或其溶剂化物,其中所有基团在申请和权利要求书中定义。 根据本发明的化合物是代谢型谷氨酸受体亚型2(“mGluR2”)的正变构调节剂,其可用于治疗或预防与谷氨酸功能障碍相关的神经和精神病学障碍以及涉及代谢型受体的mGluR2亚型的疾病 。 特别地,这些疾病是选自焦虑,精神分裂症,偏头痛,抑郁症和癫痫组的中枢神经系统疾病。 本发明还涉及药物组合物和制备这些化合物和这些组合物的方法,以及这些化合物用于预防和治疗其中涉及mGluR2的疾病的用途。

    INDOLE AND BENZOMORPHOLINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
    6.
    发明申请
    INDOLE AND BENZOMORPHOLINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS 有权
    作为代谢型谷氨酸盐受体的调节剂的吲哚和苯并吡喃衍生物

    公开(公告)号:US20110275624A1

    公开(公告)日:2011-11-10

    申请号:US13123984

    申请日:2009-10-15

    摘要: The present invention relates to novel compounds, in particular novel indole and benzomorpholine derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors-subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.

    摘要翻译: 本发明涉及新的化合物,特别是根据式(I)的新的吲哚和苯并吗啉衍生物,其中所有基团如申请和权利要求中所定义。 根据本发明的化合物是代谢型受体亚型2(“mGluR2”)的正性变构调节剂,其可用于治疗或预防与谷氨酸功能障碍相关的神经和精神障碍以及参与代谢型受体的mGluR2亚型的疾病 。 特别地,这些疾病是选自焦虑,精神分裂症,偏头痛,抑郁症和癫痫组的中枢神经系统疾病。 本发明还涉及制备这些化合物和组合物的药物组合物和方法,以及这些化合物用于预防和治疗其中涉及mGluR2的疾病的用途。